Compare FLGT & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLGT | AUTL |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 511.0M | 596.2M |
| IPO Year | 2016 | 2025 |
| Metric | FLGT | AUTL |
|---|---|---|
| Price | $21.63 | $1.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $8.73 |
| AVG Volume (30 Days) | 286.8K | ★ 1.4M |
| Earning Date | 11-06-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $18,730,000.00 | $10,120,000.00 |
| Revenue This Year | $2.80 | $98.68 |
| Revenue Next Year | $15.38 | $28.47 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $13.46 | $1.18 |
| 52 Week High | $31.04 | $2.58 |
| Indicator | FLGT | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 54.75 | 41.97 |
| Support Level | $19.12 | $1.37 |
| Resistance Level | $23.83 | $1.92 |
| Average True Range (ATR) | 0.86 | 0.09 |
| MACD | -0.15 | -0.01 |
| Stochastic Oscillator | 60.98 | 25.00 |
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.